Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment.
View/ Open
Date
2021-07-19Author
Pasha, N
Turner, NC
Type
Journal Article
Metadata
Show full item recordAbstract
Rational development of targeted therapies has revolutionized metastatic breast cancer outcomes, although resistance to treatment remains a major challenge. Advances in molecular profiling and imaging technologies have provided evidence for the impact of clonal diversity in cancer treatment resistance, through the outgrowth of resistant clones. In this Review, we focus on the genomic processes that drive tumoral heterogeneity and the mechanisms of resistance underlying metastatic breast cancer treatment and discuss implications for future treatment strategies.
Collections
Subject
Science & Technology
Life Sciences & Biomedicine
Oncology
FIRST-LINE THERAPY
PHASE-III
TRASTUZUMAB EMTANSINE
POSTMENOPAUSAL WOMEN
CLONAL EVOLUTION
ESR1 MUTATIONS
DOUBLE-BLIND
INTRATUMOR HETEROGENEITY
ARTIFICIAL-INTELLIGENCE
MOLECULAR PORTRAITS
Research team
Molecular Oncology
Language
eng
Date accepted
2021-06-02
License start date
2021-07-19
Citation
NATURE CANCER, 2021, 2 (7), pp. 680 - 692 (13)
Publisher
NATURE PORTFOLIO